Research
Hormonal
High-dose GLP-1 receptor agonists (semaglutide 2.4 mg/week) and dual GLP-1/GIP agonists (tirzepatide 15 mg/week) produce substantial weight loss (>15% and >20% respectively) in non-diabetic obese individuals, with efficacy maintained over 2 years.
For non-diabetic individuals with obesity, weekly injections of semaglutide (2.4 mg) or tirzepatide (15 mg), combined with a reduced-calorie diet and exercise, can lead to 15-20% body weight loss over two years. Expect initial gastrointestinal side effects like nausea, which usually subside within a few months as the dose is gradually increased.
StrongSupportsVERY_HIGH confidence
The STEP trial programme assessed the effect of a high dose of the GLP-1RA semaglutide (2.4 mg once weekly by subcutaneous injection: Weygovy) and typically noted about a 15% reduction in body weight during treatment periods up to 2 years in overweight and obese adults who did not have T2DM... The design of the SURMOUNT trial programme with the synthetic dual GLP-1R/GIPR agonist tirzepatide... typically reduced body weight by about 20% during treatment periods up to 2 years in overweight and obese adults who did not have T2DM
Why this rating
Based on multiple large-scale, randomized, placebo-controlled Phase 3 clinical trials (STEP 1-5, SURMOUNT-1, 3).
Source
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Clifford J. Bailey et al. · Peptides · 2024
narrative_reviewCited 20×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →